Altretamine
| Title | Journal |
|---|---|
| Therapeutic strategies in epithelial ovarian cancer. | Journal of experimental & clinical cancer research : CR 20120101 |
| A data-driven predictive approach for drug delivery using machine learning techniques. | PloS one 20120101 |
| Increased nephrotoxicity after combined administration of melamine and cyanuric Acid in rats. | Laboratory animal research 20110301 |
| Increased paclitaxel cytotoxicity against cancer cell lines using a novel functionalized carbon nanotube. | International journal of nanomedicine 20110101 |
| Concordance of self-reported and medical chart information on cancer diagnosis and treatment. | BMC medical research methodology 20110101 |
| Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. | International journal of nanomedicine 20110101 |
| Brain metastases from ovarian carcinoma. | ISRN oncology 20110101 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation. | Drug delivery 20100401 |
| Cancer-drug associations: a complex system. | PloS one 20100101 |
| Clinical trials and progress with paclitaxel in ovarian cancer. | International journal of women's health 20100101 |
| Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy. | Journal of Korean medical science 20090801 |
| Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. | Journal of ovarian research 20090101 |
| Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model. | Cancer chemotherapy and pharmacology 20081201 |
| Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. | Journal of medicinal chemistry 20081113 |
| Relationship between frailty and cognitive decline in older Mexican Americans. | Journal of the American Geriatrics Society 20081001 |
| Atom efficient cyclotrimerization of dimethylcyanamide catalyzed by aluminium amide: a combined experimental and theoretical investigation. | Chemical communications (Cambridge, England) 20080821 |
| Lessons from a time capsule: evolution, not revolution, in therapy for advanced non-small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080701 |
| Synthesis and cytotoxic activity of trisubstituted-1,3,5-triazines. | Bioorganic & medicinal chemistry letters 20070615 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060320 |
| Topotecan: weighing in when there are many options. | The oncologist 20051001 |
| Better treatments improve survival of CHD patients. | The Nurse practitioner 20050901 |
| Emerging drugs for ovarian cancer. | Expert opinion on emerging drugs 20050501 |
| Recurrent ovarian cancer: how important is it to treat to disease progression? | Clinical cancer research : an official journal of the American Association for Cancer Research 20041115 |
| Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site. | British journal of cancer 20040517 |
| A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. | British journal of cancer 20040223 |
| Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? | British journal of cancer 20040126 |
| Oral altretamine used as salvage therapy in recurrent ovarian cancer. | Gynecologic oncology 20040101 |
| Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20040101 |
| Oral melphalan as a treatment for platinum-resistant ovarian cancer. | British journal of cancer 20030616 |
| Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. | Gynecologic oncology 20030201 |
| Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. | BMC cancer 20030101 |
| Medication sheets for patients. Oral chemotherapy. | Clinical journal of oncology nursing 20030101 |
| Oral cancer treatment: developments in chemotherapy and beyond. | British journal of cancer 20021021 |
| Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. | The Lancet. Oncology 20020901 |
| A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site. | British journal of cancer 20020422 |
| Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. | The Journal of biological chemistry 20020419 |
| Solvent, emulsifier and drug concentration factors in poly(D,L-lactic acid) microspheres containing hexamethylmelamine. | Journal of microencapsulation 20020101 |
| Recent advances in the treatment of epithelial ovarian cancer. | Expert opinion on investigational drugs 20010901 |
| Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). | Gynecologic oncology 20010801 |
| A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer. | Cancer chemotherapy and pharmacology 20010801 |
| Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. | Gynecologic oncology 20010401 |
| Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. | Japanese journal of clinical oncology 20010201 |
| Altretamine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group trial. | Investigational new drugs 20010101 |
| A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. | Health technology assessment (Winchester, England) 20010101 |
| Clinical pharmacokinetics of altretamine. | Clinical pharmacokinetics 19950601 |
| The w/w+ SMART is a useful tool for the evaluation of pesticides. | Mutagenesis 19940701 |
| Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. | Cancer 19901015 |
| Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. | Lancet (London, England) 19840915 |
| Orthostatic hypotension as a complication of hexamethylmelamine antidepressant interaction. | Cancer treatment reports 19830501 |
| A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer. | Gynecologic oncology 19830401 |
| Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies. | British journal of cancer 19830101 |
| Hexamethylmelamine chemotherapy for disseminated endometrial cancer. | Obstetrics and gynecology 19810901 |
| Single-agent chemotherapy for recurrent carcinoma of the cervix. | Cancer clinical trials 19800101 |
| Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study. | Cancer treatment reports 19790801 |
| Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer. | American journal of obstetrics and gynecology 19790401 |